Business Wire

INTRESO

20.6.2024 08:01:34 CEST | Business Wire | Press release

Share
INTRESO Highlights Sustainable Alternatives as EU Considers a Ban on Sulfuryl Fluoride

International Treatment Solutions (INTRESO) Group has written to the EU Commission’s Standing Committee on Biocidal Products to highlight the availability of safe, effective and environmentally sustainable alternatives to sulfuryl fluoride, ahead of a 21 June meeting which will consider a ban of the chemical for the preservation treatment of wood [PT8], and as an insecticide and acaricide for the control of insects and arachnids [PT18].

On 21 June, representatives from EU Member States will vote on a proposal to ban the use of sulfuryl fluoride, an extremely harmful synthetic greenhouse gas with a global warming potential more than 4500 times that of carbon dioxide, for these fumigation purposes. In what amounts to an effective ban, the EU is considering withdrawing approvals for the continued biocidal use of sulfuryl fluoride, due to a lack of data on the potential risks to human health posed by the chemical.

INTRESO Group produces BLUEFUME™, a highly effective and environmentally sustainable drop-in replacement for sulfuryl fluoride. BLUEFUME™ is the latest iteration of a tried and tested chemical, HCN, successfully used around the world for decades. INTRESO Group’s product is fully approved in numerous markets including in the EU, UK, Australia, New Zealand, Malaysia, Morocco and South Africa. Most recently, it has been put through rigorous testing and approval processes in Australia in 2023, with subsequent regulatory approval demonstrating impressive results against the latest standards.

Effective and economical, BLUEFUME™ breaks down into naturally occurring substances, meaning it also has a far lower environmental footprint than sulfuryl fluoride.

Besides being a Biocidal Product, sulfuryl fluoride is also a Plant Protection Product for the treatment of tree logs exported from the EU. In which case, additionally, INTRESO Group’s proprietary product, Ethanedinitrile (EDN™), is a highly effective and environmentally sustainable drop-in replacement for sulfuryl fluoride and has already been approved for the fumigation of timber and wood products in countries including Australia, New Zealand, South Korea, Malaysia, Uruguay, South Africa and Turkey. EDN was also successfully used over successive years in the Czech Republic under emergency use authorization during their recent bark beetle outbreak. This demonstrates that other major agricultural exporters have moved faster than the EU in approving alternative chemicals which adhere to stringent modern safety and environmental standards.

Commenting on the potential new restrictions on the use of sulfuryl fluoride in the EU, Kade McConville, Executive Director of INTRESO Group said:

The claims that there is no available and highly effective alternative to sulfuryl fluoride for biocidal and plant protection use are simply not true. Our products, including EDN™ and BLUEFUME, are drop-in replacements that have been shown to be efficient under a wider set of climatic conditions than sulfuryl fluoride.

With increasing evidence as to the harms to human health and the planet resulting from sulfuryl fluoride, it is vitally important that EU decision-makers consider and understand the fact that alternative solutions are readily available for use in European fumigation, and that whilst sulfuryl fluoride is a tool, it is not the only tool in the toolbox.

Ahead of this pivotal vote, I have written to the Commission to make clear that our innovative, environmentally sustainable solutions already provide an effective alternative to sulfuryl fluoride in forward-thinking countries with some of the strictest biosecurity standards, including Australia and New Zealand.”

Background

  • Fumigation is essential to protect against risks of invasive pests from international trade in raw commodities, with Europe facing unprecedented levels of bark beetle breakouts in conifer forests1.
  • Sulfuryl fluoride, the most widely used fumigant in the EU, has a Global Warming Potential (GWP) more than 4500 times that of carbon dioxide.
  • Use of sulfuryl fluoride is increasingly globally.
  • Negotiations on the EU’s F-Gas Regulation, adopted in March 2024, resulted in new monitoring and recapture requirements and considered a total ban.
  • EDNTM has a GWP over 4400x lower than sulfuryl fluoride.
  • For more information on INTRESO: www.intreso.com
____________________

1

https://foresteurope.org/bark-beetle-outbreaks-in-forests-a-pan-european-view/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240619174501/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye